News
2023
-
Press Release
-
Sysmex Expands Sales of Its Reagents for Blood-based Amyloid β Testing to Europe
-
Press Release
-
Sysmex Makes Megakaryon Corporation into a Subsidiary, Aiming at Accelerating Efforts in the Field of Regenerative and Cellular Medicine
- Towards the Early Commercialization of Human iPS Cell-Derived Platelet Preparations -
-
Press Release
-
Sysmex Obtains Insurance Coverage for Its Immunoassay Reagent “HISCL™ M2BPGi™-Qt Assay Kit” for Quantitative Measurement of Hepatic Fibrosis Progression from Blood Samples
- Planned for Domestic Launch in February 2024, with Subsequent Introduction Overseas -
-
Press Release
-
Sysmex and Fujirebio Sign Agreement for the Supply of Reagent Raw Materials in the Field of Immunoassay
-
Group Company News
-
Regulatory Approval Application Filed for the Use of the hinotori™ Surgical Robot System in Respiratory Surgery (Medicaroid)
-
Information
-
Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Eighth Consecutive Year
-
Press Release
-
Sysmex to Reinforce IVD Instrument Production to Support Total Solutions in Clinical Testing
- Expansion of Subsidiary's Manufacturing Factory Ensures Stable Global Supply and Enhanced Laboratory Productivity - (PDF:249KB)
-
Press Release
-
Sysmex and Fujirebio Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration
-
Information
-
Sysmex Publishes the Sysmex Report 2023 (Integrated Report) and the Sysmex Sustainability Data Book 2023
-
Information
-
Implementing the Group-wide Unified Social Contribution Activity, the “Sysmex Gives Back Campaign”
-
Information
-
Sysmex receives the highest rating of GOLD in the “Pride Index”, for its efforts related to sexual and gender minorities, for the second year in row
-
Press Release
-
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2024
-
Press Release
-
Announcement Regarding Differences between Actual and Forecast Figures for the Six Months Ended September 30, 2023 (PDF:235KB)
-
Press Release
-
Announcement Regarding Introduction of Stock-Granting Compensation Plan (ESOP Trust) (PDF:245KB)
-
Press Release
-
AlliedCel, a Joint Venture Between Sysmex and JCR Pharmaceuticals, Has Acquired a New Pipeline to Promote the Early Social Implementation of Regenerative Medicine Products
- Securing the Manufacturing and Sales License for Regenerative Medicine Products Developed by JUNTEN BIO -
-
Information
-
Sysmex Receives “Minister of Education, Culture, Sports, Science, and Technology Prize” and Two Other Prizes at “Kinki Local Commendation for Inventions” in 2023
-
Information
-
Sysmex Group Promotes “PINKTOBER,” a Breast Cancer Awareness Campaign
-
Press Release
-
Sysmex Obtains ISO 30414 Certification for Human Capital Reporting
- Implementing Human Capital Management to Achieve Sustainable Increase in Corporate Value -
-
Press Release
-
Sysmex Establishes New Open Innovation Hub “Healthcare Science Hub Tokyo”
- High-flexibility R&D hub for accelerating creative collaboration with various partners -
-
Group Company News
-
Demonstration of Remote Surgery Using the hinotori™ Surgical Robot System Successfully Performed Between Singapore and Japan (Medicaroid)
-
Press Release
-
Sysmex and Fujirebio Enter into Basic Agreement on Business Collaboration in the Field of Immunoassay
-
Information
-
Sysmex Brand Concept Movie Has Been Released
-
Group Company News
-
Medicaroid Receives Regulatory Approval of Health Science Authority in Singapore for the hinotori™ Surgical Robot System (Medicaroid)
-
Press Release
-
Sysmex’s PrismGuide™ IRD Panel System Receives Insurance Coverage as Japan’s First Gene Panel Testing System for Inherited Retinal Dystrophy
– Supporting Personalized Medicine Based on the Causative Genes of Intractable Diseases –
-
Press Release
-
Sysmex’s OncoGuide™ NCC Oncopanel System Receives Insurance Coverage as a Companion Diagnostic for Futibatinib, a Treatment for Advanced Biliary Tract Cancer
-
Press Release
-
Sysmex Begins Supplying Reagents for U.S. Based Laboratory Developed Test (LDT) Measuring Amyloid Beta (Aβ) in Blood
-
Press Release
-
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2024
-
Information
-
Sysmex Again Selected for Inclusion in All ESG Indices adopted by the Government Pension Investment Fund (GPIF)
-
Press Release
-
Sysmex Expands Long-Term Alliance with Roche
-
Press Release
-
Project on the Utilization of Caresphere™, a Network Solution to Support Laboratory Testing Quality Control for the Republic of Ghana, Selected by METI for a Publicly Solicited Project
- Sysmex Launches a Feasibility Study on Using DX to Improve the Quality of Laboratory Testing in African Countries -
-
Press Release
-
Our Views and Policy Regarding Investment Unit Reduction (PDF:129KB)
-
Group Company News
-
OGT announces commercial partnership with Applied Spectral Imaging (OGT)
-
Press Release
-
Sysmex Launches World's First Point-of-Care Testing System in Europe to Detect Antimicrobial Susceptibility in Just 30 Minutes
- By Revolutionizing Conventional Clinical Workflow, Our Diagnostic Technology Confronts the Global Threat of Antimicrobial Resistance (AMR) -
-
Press Release
-
Sysmex Launches an Assay Kit to Identify Amyloid Beta (Aβ) Accumulation in the Brain, a Cause of Alzheimer’s Disease, Using a Small Amount of Blood
- Measurement of Plasma Aβ Using the Automated Immunoassay System HISCL™-5000/HISCL™-800 -
-
Press Release
-
Sysmex Obtains Manufacturing and Marketing Approval for its PrismGuide™ IRD Panel System as Japan’s First Gene Panel Testing System for Inherited Retinal Dystrophy
- Contributing to Improving the QOL of Patients by Supporting Personalized Diagnosis Based on Causative Genes -
-
Press Release
-
Sysmex Launches Clinical Flow Cytometry System in Japan
- Realizing Higher Efficiency and Standardization of Flow Cytometry (FCM) Testing -
-
Press Release
-
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2023
-
Press Release
-
Sysmex Announces Changes from Financial Forecasts and Year-End Dividend (Commemorative Dividend) for the Fiscal Year Ended March 31, 2023 (PDF:186KB)
-
Press Release
-
Announcement of Executive Change (PDF:140KB)
-
Press Release
-
Sysmex Group Formulates a Long-Term Corporate Strategy and Mid-Term Management Plan
- Starting a New Challenge for the Next Decade -
-
Press Release
-
Sysmex Formulates “Sysmex Eco-Vision 2033”
- Recognizing the relationship between the environment and health, we will collaboratively create innovative solutions that will advance the realization of a circular society -
-
Group Company News
-
Regulatory Approval Application Filed with the Health Sciences Authority in Singapore for the “hinotori™ Surgical Robot System” (Medicaroid)
-
Press Release
-
Sysmex to Establish New Manufacturing Base in India
- Creating a Manufacturing Structure in India to Support Sustainable Growth -
-
Group Company News
-
Sysmex Inostics and Genomic Testing Cooperative Form Partnership to Accelerate Therapeutic Discovery and Development (Sysmex Inostics)
-
Group Company News
-
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC (Riken Genesis)
-
Group Company News
-
Medicaroid Announces Top Management Changes (Medicaroid)
-
Press Release
-
Sysmex Receives Approval for a Partial Change to the OncoGuide™ NCC Oncopanel System as a Companion Diagnostic to Futibatinib for Biliary Tract Cancer
-
Group Company News
-
OGT first to achieve IVDR-certification for FISH probes (OGT)
-
Press Release
-
Announcement of Organizational and Personnel Changes (PDF:200KB)
-
Press Release
-
Sysmex and Siemens Healthineers Establish Global Agreement to Supply Hemostasis Instruments and Reagents as OEMs
-
Press Release
-
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2023
-
Press Release
-
Notice of Changes in Representative Directors